Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.
Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy.
复制标题
DOI：
10.1007/s00520-014-2424-8
复制
发表时间：
2015-04
影响因子：
3.1
通讯作者：
Loprinzi, Charles L.
中科院分区：
文献类型：
--
作者：
Pachman, Deirdre R.;Weisbrod, Breanna L.;Seisler, Drew K.;Barton, Debra L.;Fee-Schroeder, Kelliann C.;Smith, Thomas J.;Lachance, Daniel H.;Liu, Heshan;Shelerud, Randy A.;Cheville, Andrea L.;Loprinzi, Charles L.
化疗引起的周围神经病变（CIPN）是化疗的常见副作用，需要更好的有效治疗。初步数据支持使用扰频器疗法，一种通过无创皮肤电刺激治疗疼痛的设备，用于治疗CIPN。目前的手稿报告了一项试点试验的数据，该试验旨在调查扰频器治疗已建立的CIPN的效果。符合条件的患者在前一周有CIPN症状持续≥1个月，刺痛和/或疼痛≥4/10。患者使用扰频器治疗受影响的区域，每天最多10次，每次30分钟。使用由数值模拟量表组成的神经病变问卷监测症状，从0到10，治疗前每天以及治疗后10周每周。描述性汇总统计构成了数据分析的基础。37名患者入组。25名患者主要接受下肢治疗，12名患者主要接受上肢治疗。从基线到第10天，疼痛评分降低了53%；刺痛减少44%；麻木感减少37%。这种益处似乎持续了10周的随访。没有明显的不良事件。初步数据支持扰频器治疗CIPN可能有效：需要进行前瞻性安慰剂对照临床试验。
Chemotherapy-induced peripheral neuropathy (CIPN), a common side effect of chemotherapy, needs better effective treatments. Preliminary data support the use of Scrambler therapy, a device which treats pain via noninvasive cutaneous electrostimulation, for the treatment of CIPN. The current manuscript reports data from a pilot trial, performed to investigate the effect of Scrambler therapy for the treatment of established CIPN. Eligible patients had CIPN symptoms of ≥1 month duration with tingling and/or pain ≥4/10 during the prior week. Patients were treated with Scrambler therapy to the affected area(s) for up to ten daily 30-min sessions. Symptoms were monitored using a neuropathy questionnaire consisting of numerical analog scales ranging from 0 to 10, daily before therapy as well as weekly for 10 weeks after therapy. Descriptive summary statistics formed the basis of data analysis. Thirty-seven patients were enrolled. Twenty-five patients were treated primarily on their lower extremities while 12 were treated primarily on their upper extremities. There was a 53 % reduction in pain score from baseline to day 10; a 44%reduction in tingling; and a 37%reduction in numbness. Benefit appeared to last throughout 10 weeks of follow-up. There were no substantial adverse events. Preliminary data support that Scrambler therapy may be effective for the treatment of CIPN: a prospective placebo-controlled clinical trial should be performed.
登录
查看更多内容
影响因子：
6.2
作者：
Rao, Ravi D.;Michalak, John C.;Wong, Gilbert Y.
通讯作者：
Wong, Gilbert Y.
影响因子：
4.7
作者：
Locke, Dona E. C.;Decker, Paul A.;Buckner, Jan C.
通讯作者：
Buckner, Jan C.
影响因子：
6.2
作者：
Rao, Ravi D.;Flynn, Patrick J.;Loprinzi, Charles L.
通讯作者：
Loprinzi, Charles L.
影响因子：
7.4
作者：
Hammack, JE;Michalak, JC;Johnson, JA
通讯作者：
Johnson, JA
影响因子：
3.5
作者：
K채stenbauer, T;Sauseng, S;Irsigler, K
通讯作者：
Irsigler, K